13 results
Type 1 Second-degree AV block, also known as Mobitz I or Wenckebach periodicity, is almost always
also known as Mobitz ... interval on the electrocardiogram ... #Clinical #EM #IM ... MedStudent #EKG #MobitzI ... #Mobitz1 #Mobitz
Type 1 Second-degree AV block, also known as Mobitz I or Wenckebach periodicity, is almost always
also known as Mobitz ... interval on the electrocardiogram ... #Clinical #EM #IM ... MedStudent #EKG #MobitzI ... #Mobitz1 #Mobitz
Mobitz II heart block is characterized on a surface ECG by intermittently nonconducted P waves not
Mobitz II heart ... in describing Mobitz ... #Clinical #EM #IM ... MedStudent #EKG #MobitzII ... #Mobitz2 #Mobitz
Murmurs Needing Echocardiography Evaluation #Management #EM #IM #Cardiology #Murmur #Benign #Characteristics #Echocardiogram #ALiEM
Evaluation #Management #EM ... #IM #Cardiology ... Echocardiogram #ALiEM
Approach to ECGs - Tachy/Bradyarrhythmias
Tachyarrhythmias - HR > 100
Wide
  (1) VT - DANGER
  (2)
(3) SVTs - atrial ... longer pause 2º - Mobitz ... 3, etc.) 2º - Mobitz ... II / Mobitz - , ... EKG #diagnosis #electrocardiogram
Cardiac etiologies of syncope (red line above) have the highest associated mortality! #EBM #EM #IM #Cardiology
#EBM #EM #IM #Cardiology ... Cardiac #Mortality #ALiEM
Stroke Rate by CHADS2 Score (Gage et al., JAMA, 2001) https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607 #EBM #EM #IM #Cardiology #CHADS2
term=11401607 #EBM ... #EM #IM #Cardiology ... Score #StrokeRate #ALiEM
Summary of Heart Blocks
1st Degree Heart Block:
 • Prolonged PR >200ms (5 small squares).
 • Narrow
Treatment 2nd Degree, Mobitz ... . 2nd Degree, Mobitz ... P and QRS • Atrial ... Diagnosis #EKG #electrocardiogram
Typical ECG changes in acute pericarditis includes: stage 1 - diffuse, positive, ST elevations with reciprocal
leads indicates atrial ... inverted #Diagnosis #EM ... #IM #Cardiology
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
, According to Trial ... Group #EBM #Neuro ... #IM #Fremanezumab